ID   MDR3_HUMAN              Reviewed;        1286 AA.
AC   P21439; A0A2V7; A4D1D3; A4D1D4; A4D1D5; D6W5P3; D6W5P4; Q14813;
DT   01-MAY-1991, integrated into UniProtKB/Swiss-Prot.
DT   20-FEB-2007, sequence version 2.
DT   10-MAY-2017, entry version 177.
DE   RecName: Full=Phosphatidylcholine translocator ABCB4 {ECO:0000305};
DE   AltName: Full=ATP-binding cassette sub-family B member 4 {ECO:0000312|HGNC:HGNC:45};
DE   AltName: Full=Multidrug resistance protein 3 {ECO:0000303|PubMed:2892668};
DE            EC=3.6.3.44;
DE   AltName: Full=P-glycoprotein 3 {ECO:0000250|UniProtKB:Q08201};
GN   Name=ABCB4 {ECO:0000312|HGNC:HGNC:45};
GN   Synonyms=MDR3 {ECO:0000303|PubMed:2892668}, PGY3;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RX   PubMed=2906314; DOI=10.1016/0378-1119(88)90057-1;
RA   van der Bliek A.M., Kooiman P.M., Schneider C., Borst P.;
RT   "Sequence of mdr3 cDNA encoding a human P-glycoprotein.";
RL   Gene 71:401-411(1988).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], VARIANT GBD1 ASP-528, AND VARIANTS
RP   VAL-238; VAL-263; GLN-590; ASN-651; GLY-652 AND GLN-788.
RG   NIEHS SNPs program;
RL   Submitted (OCT-2006) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=12853948; DOI=10.1038/nature01782;
RA   Hillier L.W., Fulton R.S., Fulton L.A., Graves T.A., Pepin K.H.,
RA   Wagner-McPherson C., Layman D., Maas J., Jaeger S., Walker R.,
RA   Wylie K., Sekhon M., Becker M.C., O'Laughlin M.D., Schaller M.E.,
RA   Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Cordes M., Du H.,
RA   Sun H., Edwards J., Bradshaw-Cordum H., Ali J., Andrews S., Isak A.,
RA   Vanbrunt A., Nguyen C., Du F., Lamar B., Courtney L., Kalicki J.,
RA   Ozersky P., Bielicki L., Scott K., Holmes A., Harkins R., Harris A.,
RA   Strong C.M., Hou S., Tomlinson C., Dauphin-Kohlberg S.,
RA   Kozlowicz-Reilly A., Leonard S., Rohlfing T., Rock S.M.,
RA   Tin-Wollam A.-M., Abbott A., Minx P., Maupin R., Strowmatt C.,
RA   Latreille P., Miller N., Johnson D., Murray J., Woessner J.P.,
RA   Wendl M.C., Yang S.-P., Schultz B.R., Wallis J.W., Spieth J.,
RA   Bieri T.A., Nelson J.O., Berkowicz N., Wohldmann P.E., Cook L.L.,
RA   Hickenbotham M.T., Eldred J., Williams D., Bedell J.A., Mardis E.R.,
RA   Clifton S.W., Chissoe S.L., Marra M.A., Raymond C., Haugen E.,
RA   Gillett W., Zhou Y., James R., Phelps K., Iadanoto S., Bubb K.,
RA   Simms E., Levy R., Clendenning J., Kaul R., Kent W.J., Furey T.S.,
RA   Baertsch R.A., Brent M.R., Keibler E., Flicek P., Bork P., Suyama M.,
RA   Bailey J.A., Portnoy M.E., Torrents D., Chinwalla A.T., Gish W.R.,
RA   Eddy S.R., McPherson J.D., Olson M.V., Eichler E.E., Green E.D.,
RA   Waterston R.H., Wilson R.K.;
RT   "The DNA sequence of human chromosome 7.";
RL   Nature 424:157-164(2003).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=12690205; DOI=10.1126/science.1083423;
RA   Scherer S.W., Cheung J., MacDonald J.R., Osborne L.R., Nakabayashi K.,
RA   Herbrick J.-A., Carson A.R., Parker-Katiraee L., Skaug J., Khaja R.,
RA   Zhang J., Hudek A.K., Li M., Haddad M., Duggan G.E., Fernandez B.A.,
RA   Kanematsu E., Gentles S., Christopoulos C.C., Choufani S.,
RA   Kwasnicka D., Zheng X.H., Lai Z., Nusskern D.R., Zhang Q., Gu Z.,
RA   Lu F., Zeesman S., Nowaczyk M.J., Teshima I., Chitayat D., Shuman C.,
RA   Weksberg R., Zackai E.H., Grebe T.A., Cox S.R., Kirkpatrick S.J.,
RA   Rahman N., Friedman J.M., Heng H.H.Q., Pelicci P.G., Lo-Coco F.,
RA   Belloni E., Shaffer L.G., Pober B., Morton C.C., Gusella J.F.,
RA   Bruns G.A.P., Korf B.R., Quade B.J., Ligon A.H., Ferguson H.,
RA   Higgins A.W., Leach N.T., Herrick S.R., Lemyre E., Farra C.G.,
RA   Kim H.-G., Summers A.M., Gripp K.W., Roberts W., Szatmari P.,
RA   Winsor E.J.T., Grzeschik K.-H., Teebi A., Minassian B.A., Kere J.,
RA   Armengol L., Pujana M.A., Estivill X., Wilson M.D., Koop B.F.,
RA   Tosi S., Moore G.E., Boright A.P., Zlotorynski E., Kerem B.,
RA   Kroisel P.M., Petek E., Oscier D.G., Mould S.J., Doehner H.,
RA   Doehner K., Rommens J.M., Vincent J.B., Venter J.C., Li P.W.,
RA   Mural R.J., Adams M.D., Tsui L.-C.;
RT   "Human chromosome 7: DNA sequence and biology.";
RL   Science 300:767-772(2003).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-72 (ISOFORM 1).
RC   TISSUE=Liver;
RX   PubMed=7893760; DOI=10.1016/0167-4781(94)00214-N;
RA   Smit J.J., Mol C.A., van Deemter L., Wagenaar E., Schinkel A.H.,
RA   Borst P.;
RT   "Characterization of the promoter region of the human MDR3 P-
RT   glycoprotein gene.";
RL   Biochim. Biophys. Acta 1261:44-56(1995).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 856-1286 (ISOFORM 1), AND ALTERNATIVE
RP   SPLICING.
RX   PubMed=2892668;
RA   van der Bliek A.M., Baas F., ten Houte de Lange T., Kooiman P.M.,
RA   van der Velde-Koerts T., Borst P.;
RT   "The human mdr3 gene encodes a novel P-glycoprotein homologue and
RT   gives rise to alternatively spliced mRNAs in liver.";
RL   EMBO J. 6:3325-3331(1987).
RN   [8]
RP   GENE STRUCTURE.
RX   PubMed=2002063;
RA   Lincke C.R., Smit J.J.M., van der Velde-Koerts T., Borst P.;
RT   "Structure of the human MDR3 gene and physical mapping of the human
RT   MDR locus.";
RL   J. Biol. Chem. 266:5303-5310(1991).
RN   [9]
RP   FUNCTION.
RX   PubMed=7957936; DOI=10.1016/0014-5793(94)01135-4;
RA   Smith A.J., Timmermans-Hereijgers J.L., Roelofsen B., Wirtz K.W.,
RA   van Blitterswijk W.J., Smit J.J., Schinkel A.H., Borst P.;
RT   "The human MDR3 P-glycoprotein promotes translocation of
RT   phosphatidylcholine through the plasma membrane of fibroblasts from
RT   transgenic mice.";
RL   FEBS Lett. 354:263-266(1994).
RN   [10]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=8898203; DOI=10.1016/S0092-8674(00)81370-7;
RA   van Helvoort A., Smith A.J., Sprong H., Fritzsche I., Schinkel A.H.,
RA   Borst P., van Meer G.;
RT   "MDR1 P-glycoprotein is a lipid translocase of broad specificity,
RT   while MDR3 P-glycoprotein specifically translocates
RT   phosphatidylcholine.";
RL   Cell 87:507-517(1996).
RN   [11]
RP   FUNCTION.
RX   PubMed=9366571; DOI=10.1172/JCI119799;
RA   Crawford A.R., Smith A.J., Hatch V.C., Oude Elferink R.P., Borst P.,
RA   Crawford J.M.;
RT   "Hepatic secretion of phospholipid vesicles in the mouse critically
RT   depends on mdr2 or MDR3 P-glycoprotein expression. Visualization by
RT   electron microscopy.";
RL   J. Clin. Invest. 100:2562-2567(1997).
RN   [12]
RP   INVOLVEMENT IN PFIC3.
RX   PubMed=9419367; DOI=10.1073/pnas.95.1.282;
RA   de Vree J.M.L., Jacquemin E., Sturm E., Cresteil D., Bosma P.J.,
RA   Aten J., Deleuze J.-F., Desrochers M., Burdelski M., Bernard O.,
RA   Oude Elferink R.P.J., Hadchouel M.;
RT   "Mutations in the MDR3 gene cause progressive familial intrahepatic
RT   cholestasis.";
RL   Proc. Natl. Acad. Sci. U.S.A. 95:282-287(1998).
RN   [13]
RP   SUBCELLULAR LOCATION, AND INDUCTION.
RX   PubMed=15258199; DOI=10.1194/jlr.M400132-JLR200;
RA   Shoda J., Inada Y., Tsuji A., Kusama H., Ueda T., Ikegami T.,
RA   Suzuki H., Sugiyama Y., Cohen D.E., Tanaka N.;
RT   "Bezafibrate stimulates canalicular localization of NBD-labeled PC in
RT   HepG2 cells by PPARalpha-mediated redistribution of ABCB4.";
RL   J. Lipid Res. 45:1813-1825(2004).
RN   [14]
RP   FUNCTION, ENZYME REGULATION, GLYCOSYLATION, AND MUTAGENESIS OF LYS-435
RP   AND LYS-1075.
RX   PubMed=17523162; DOI=10.1002/hep.21591;
RA   Morita S.Y., Kobayashi A., Takanezawa Y., Kioka N., Handa T., Arai H.,
RA   Matsuo M., Ueda K.;
RT   "Bile salt-dependent efflux of cellular phospholipids mediated by ATP
RT   binding cassette protein B4.";
RL   Hepatology 46:188-199(2007).
RN   [15]
RP   INTERACTION WITH RACK1, AND SUBCELLULAR LOCATION.
RX   PubMed=19674157; DOI=10.1111/j.1872-034X.2009.00544.x;
RA   Ikebuchi Y., Takada T., Ito K., Yoshikado T., Anzai N., Kanai Y.,
RA   Suzuki H.;
RT   "Receptor for activated C-kinase 1 regulates the cellular localization
RT   and function of ABCB4.";
RL   Hepatol. Res. 39:1091-1107(2009).
RN   [16]
RP   FUNCTION, GLYCOSYLATION, AND SUBCELLULAR LOCATION.
RX   PubMed=21820390; DOI=10.1053/j.gastro.2011.07.042;
RA   Groen A., Romero M.R., Kunne C., Hoosdally S.J., Dixon P.H.,
RA   Wooding C., Williamson C., Seppen J., Van den Oever K., Mok K.S.,
RA   Paulusma C.C., Linton K.J., Oude Elferink R.P.;
RT   "Complementary functions of the flippase ATP8B1 and the floppase ABCB4
RT   in maintaining canalicular membrane integrity.";
RL   Gastroenterology 141:1927-1937(2011).
RN   [17]
RP   FUNCTION, SUBCELLULAR LOCATION, AND ENZYME REGULATION.
RX   PubMed=23468132; DOI=10.1194/jlr.M032425;
RA   Morita S.Y., Tsuda T., Horikami M., Teraoka R., Kitagawa S.,
RA   Terada T.;
RT   "Bile salt-stimulated phospholipid efflux mediated by ABCB4 localized
RT   in nonraft membranes.";
RL   J. Lipid Res. 54:1221-1230(2013).
RN   [18]
RP   SUBCELLULAR LOCATION, AND INDUCTION.
RX   PubMed=24122873; DOI=10.1002/hep.26894;
RA   Ghonem N.S., Ananthanarayanan M., Soroka C.J., Boyer J.L.;
RT   "Peroxisome proliferator-activated receptor alpha activates human
RT   multidrug resistance transporter 3/ATP-binding cassette protein
RT   subfamily B4 transcription and increases rat biliary
RT   phosphatidylcholine secretion.";
RL   Hepatology 59:1030-1042(2014).
RN   [19]
RP   FUNCTION, SUBCELLULAR LOCATION, CHARACTERIZATION OF VARIANTS PFIC3
RP   VAL-286 AND PHE-320, AND MUTAGENESIS OF ALA-953.
RX   PubMed=24806754; DOI=10.1002/hep.26970;
RA   Andress E.J., Nicolaou M., Romero M.R., Naik S., Dixon P.H.,
RA   Williamson C., Linton K.J.;
RT   "Molecular mechanistic explanation for the spectrum of cholestatic
RT   disease caused by the S320F variant of ABCB4.";
RL   Hepatology 59:1921-1931(2014).
RN   [20]
RP   VARIANT ICP3 ASP-546, AND CHARACTERIZATION OF VARIANT ICP3 ASP-546.
RX   PubMed=10767346; DOI=10.1093/hmg/9.8.1209;
RA   Dixon P.H., Weerasekera N., Linton K.J., Donaldson O., Chambers J.,
RA   Egginton E., Weaver J., Nelson-Piercy C., de Swiet M., Warnes G.,
RA   Elias E., Higgins C.F., Johnston D.G., McCarthy M.I., Williamson C.;
RT   "Heterozygous MDR3 missense mutation associated with intrahepatic
RT   cholestasis of pregnancy: evidence for a defect in protein
RT   trafficking.";
RL   Hum. Mol. Genet. 9:1209-1217(2000).
RN   [21]
RP   VARIANTS PFIC3 ARG-138; ILE-346; GLY-395; ALA-424; MET-425; PHE-541;
RP   ARG-556; GLY-564; SER-711 AND SER-983, AND VARIANT GLY-652.
RX   PubMed=11313315; DOI=10.1053/gast.2001.23984;
RA   Jacquemin E., De Vree J.M.L., Cresteil D., Sokal E.M., Sturm E.,
RA   Dumont M., Scheffer G.L., Paul M., Burdelski M., Bosma P.J.,
RA   Bernard O., Hadchouel M., Elferink R.P.;
RT   "The wide spectrum of multidrug resistance 3 deficiency: from neonatal
RT   cholestasis to cirrhosis of adulthood.";
RL   Gastroenterology 120:1448-1458(2001).
RN   [22]
RP   VARIANTS GBD1 PHE-320 AND SER-1168, AND VARIANT ALA-175.
RX   PubMed=11313316; DOI=10.1053/gast.2001.23947;
RA   Rosmorduc O., Hermelin B., Poupon R.;
RT   "MDR3 gene defect in adults with symptomatic intrahepatic and
RT   gallbladder cholesterol cholelithiasis.";
RL   Gastroenterology 120:1459-1467(2001).
RN   [23]
RP   VARIANT PFIC3 ASP-535.
RX   PubMed=12671900; DOI=10.1053/gast.2003.50144;
RA   Lucena J.-F., Herrero J.I., Quiroga J., Sangro B.,
RA   Garcia-Foncillas J., Zabalegui N., Sola J., Herraiz M., Medina J.F.,
RA   Prieto J.;
RT   "A multidrug resistance 3 gene mutation causing cholelithiasis,
RT   cholestasis of pregnancy, and adulthood biliary cirrhosis.";
RL   Gastroenterology 124:1037-1042(2003).
RN   [24]
RP   VARIANTS GBD1 ILE-165; THR-301; PHE-320; ASP-528; GLN-591 AND
RP   SER-1168, AND VARIANTS ALA-175; GLN-590; GLY-652; SER-742; GLN-788 AND
RP   THR-934.
RX   PubMed=12891548; DOI=10.1016/S0016-5085(03)00898-9;
RA   Rosmorduc O., Hermelin B., Boelle P.Y., Parc R., Taboury J.,
RA   Poupon R.;
RT   "ABCB4 gene mutation-associated cholelithiasis in adults.";
RL   Gastroenterology 125:452-459(2003).
RN   [25]
RP   VARIANT ICP3 LYS-150, AND VARIANT GLY-652.
RX   PubMed=12746424; DOI=10.1136/jmg.40.5.e70;
RA   Muellenbach R., Linton K.J., Wiltshire S., Weerasekera N.,
RA   Chambers J., Elias E., Higgins C.F., Johnston D.G., McCarthy M.I.,
RA   Williamson C.;
RT   "ABCB4 gene sequence variation in women with intrahepatic cholestasis
RT   of pregnancy.";
RL   J. Med. Genet. 40:E70-E70(2003).
RN   [26]
RP   VARIANTS ALA-175; GLY-652 AND MET-775, AND VARIANTS ICP3 PHE-320;
RP   ASP-528 AND GLU-762.
RX   PubMed=15077010; DOI=10.1097/00008571-200402000-00003;
RA   Pauli-Magnus C., Lang T., Meier Y., Zodan-Marin T., Jung D.,
RA   Breymann C., Zimmermann R., Kenngott S., Beuers U., Reichel C.,
RA   Kerb R., Penger A., Meier P.J., Kullak-Ublick G.A.;
RT   "Sequence analysis of bile salt export pump (ABCB11) and multidrug
RT   resistance p-glycoprotein 3 (ABCB4, MDR3) in patients with
RT   intrahepatic cholestasis of pregnancy.";
RL   Pharmacogenetics 14:91-102(2004).
RN   [27]
RP   VARIANTS GLU-87; SER-95; ALA-175; VAL-367; GLY-450; GLN-590 AND
RP   GLY-652.
RX   PubMed=16763017; DOI=10.1124/dmd.105.008854;
RA   Lang T., Haberl M., Jung D., Drescher A., Schlagenhaufer R., Keil A.,
RA   Mornhinweg E., Stieger B., Kullak-Ublick G.A., Kerb R.;
RT   "Genetic variability, haplotype structures, and ethnic diversity of
RT   hepatic transporters MDR3 (ABCB4) and bile salt export pump
RT   (ABCB11).";
RL   Drug Metab. Dispos. 34:1582-1599(2006).
RN   [28]
RP   VARIANTS PFIC3 GLU-126; PRO-250; VAL-286; PHE-320; LEU-357; VAL-364;
RP   HIS-403; ALA-475; THR-511; LYS-558; ALA-593; VAL-630; PRO-701;
RP   ILE-715; GLU-723; THR-726; VAL-737; ASP-840; SER-954 AND THR-1193, AND
RP   VARIANTS ALA-175; GLN-590 AND MET-775.
RX   PubMed=17726488; DOI=10.1038/sj.ejhg.5201908;
RA   Degiorgio D., Colombo C., Seia M., Porcaro L., Costantino L.,
RA   Zazzeron L., Bordo D., Coviello D.A.;
RT   "Molecular characterization and structural implications of 25 new
RT   ABCB4 mutations in progressive familial intrahepatic cholestasis type
RT   3 (PFIC3).";
RL   Eur. J. Hum. Genet. 15:1230-1238(2007).
RN   [29]
RP   VARIANTS ALA-175; GLN-590; GLY-652; LEU-764 AND GLN-1082.
RX   PubMed=17264802; DOI=10.1097/01.fpc.0000230418.28091.76;
RA   Lang C., Meier Y., Stieger B., Beuers U., Lang T., Kerb R.,
RA   Kullak-Ublick G.A., Meier P.J., Pauli-Magnus C.;
RT   "Mutations and polymorphisms in the bile salt export pump and the
RT   multidrug resistance protein 3 associated with drug-induced liver
RT   injury.";
RL   Pharmacogenet. Genomics 17:47-60(2007).
RN   [30]
RP   VARIANTS GLN-590 AND GLY-652.
RX   PubMed=19261551; DOI=10.1016/j.dld.2008.12.101;
RA   Tavian D., Degiorgio D., Roncaglia N., Vergani P., Cameroni I.,
RA   Colombo R., Coviello D.A.;
RT   "A new splicing site mutation of the ABCB4 gene in intrahepatic
RT   cholestasis of pregnancy with raised serum gamma-GT.";
RL   Dig. Liver Dis. 41:671-675(2009).
RN   [31]
RP   VARIANTS PFIC3 ARG-70; VAL-73; PHE-320 AND HIS-403, AND VARIANT
RP   GLY-652.
RX   PubMed=21119540; DOI=10.1097/MPG.0b013e3181f50363;
RA   Colombo C., Vajro P., Degiorgio D., Coviello D.A., Costantino L.,
RA   Tornillo L., Motta V., Consonni D., Maggiore G., Balli F., Berardi S.,
RA   Calacoci M., Castellano E., Marazzi M.G., Gaslini G., D'Antiga L.,
RA   Ferretti E., Giannini A., Indolfi G., Iorio R., Martelossi S.,
RA   Moretti C., Nebbia G., Oliveri F., Poggiani C., Raggi M., Riva S.,
RA   Sciveres M., Torre G., Zancan L.;
RT   "Clinical features and genotype-phenotype correlations in children
RT   with progressive familial intrahepatic cholestasis type 3 related to
RT   ABCB4 mutations.";
RL   J. Pediatr. Gastroenterol. Nutr. 52:73-83(2011).
RN   [32]
RP   VARIANTS GBD1 MET-34; GLY-47; VAL-286 AND ASP-528, AND VARIANTS
RP   GLN-47; ALA-175; PHE-320; GLN-406; MET-775 AND THR-964.
RX   PubMed=22331132; DOI=10.1007/s00428-012-1202-6;
RA   Wendum D., Barbu V., Rosmorduc O., Arrive L., Flejou J.F., Poupon R.;
RT   "Aspects of liver pathology in adult patients with MDR3/ABCB4 gene
RT   mutations.";
RL   Virchows Arch. 460:291-298(2012).
RN   [33]
RP   VARIANTS GBD1 GLY-47; HIS-71; VAL-73; CYS-78; PHE-99; SER-124;
RP   SER-154; ILE-165; VAL-286; THR-301; PHE-320; GLY-406; SER-510;
RP   THR-511; LYS-513; ASP-528; PHE-541; HIS-545; HIS-549; THR-589;
RP   GLN-591; MET-593; LYS-647; LEU-726; LEU-729; VAL-975 AND TRP-1084, AND
RP   VARIANTS ALA-175; GLN-590; GLN-788 AND THR-934.
RX   PubMed=23533021; DOI=10.1002/hep.26424;
RA   Poupon R., Rosmorduc O., Boelle P.Y., Chretien Y., Corpechot C.,
RA   Chazouilleres O., Housset C., Barbu V.;
RT   "Genotype-phenotype relationships in the low-phospholipid-associated
RT   cholelithiasis syndrome: a study of 156 consecutive patients.";
RL   Hepatology 58:1105-1110(2013).
RN   [34]
RP   VARIANT PFIC3 ARG-481, CHARACTERIZATION OF VARIANTS PFIC3 HIS-403 AND
RP   ARG-481, FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=24045840; DOI=10.1038/ejhg.2013.214;
RA   Degiorgio D., Corsetto P.A., Rizzo A.M., Colombo C., Seia M.,
RA   Costantino L., Montorfano G., Tomaiuolo R., Bordo D., Sansanelli S.,
RA   Li M., Tavian D., Rastaldi M.P., Coviello D.A.;
RT   "Two ABCB4 point mutations of strategic NBD-motifs do not prevent
RT   protein targeting to the plasma membrane but promote MDR3
RT   dysfunction.";
RL   Eur. J. Hum. Genet. 22:633-639(2014).
RN   [35]
RP   VARIANTS GBD1 MET-34 AND GLY-47, CHARACTERIZATION OF VARIANTS GBD1
RP   MET-34 AND GLY-47, FUNCTION, SUBCELLULAR LOCATION, PHOSPHORYLATION AT
RP   THR-34, GLYCOSYLATION, MUTAGENESIS OF THR-34; THR-44 AND SER-49, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=24723470; DOI=10.1002/hep.27170;
RA   Gautherot J., Delautier D., Maubert M.A., Ait-Slimane T., Bolbach G.,
RA   Delaunay J.L., Durand-Schneider A.M., Firrincieli D., Barbu V.,
RA   Chignard N., Housset C., Maurice M., Falguieres T.;
RT   "Phosphorylation of ABCB4 impacts its function: insights from disease-
RT   causing mutations.";
RL   Hepatology 60:610-621(2014).
RN   [36]
RP   VARIANTS PFIC3 ARG-68; MET-201; HIS-459; LEU-479; PRO-978 AND
RP   LYS-1125, CHARACTERIZATION OF VARIANTS PFIC3 ARG-68; MET-201; HIS-459;
RP   LEU-479; PRO-978 AND LYS-1125, FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=24594635; DOI=10.1136/gutjnl-2014-306896;
RA   Gordo-Gilart R., Andueza S., Hierro L., Martinez-Fernandez P.,
RA   D'Agostino D., Jara P., Alvarez L.;
RT   "Functional analysis of ABCB4 mutations relates clinical outcomes of
RT   progressive familial intrahepatic cholestasis type 3 to the degree of
RT   MDR3 floppase activity.";
RL   Gut 64:147-155(2015).
CC   -!- FUNCTION: Energy-dependent phospholipid efflux translocator that
CC       acts as a positive regulator of biliary lipid secretion. Functions
CC       as a floppase that translocates specifically phosphatidylcholine
CC       (PC) from the inner to the outer leaflet of the canalicular
CC       membrane bilayer into the canaliculi of hepatocytes. Translocation
CC       of PC makes the biliary phospholipids available for extraction
CC       into the canaliculi lumen by bile salt mixed micelles and
CC       therefore protects the biliary tree from the detergent activity of
CC       bile salts (PubMed:7957936, PubMed:8898203, PubMed:9366571,
CC       PubMed:17523162, PubMed:23468132, PubMed:24806754,
CC       PubMed:24723470, PubMed:24594635, PubMed:21820390). Plays a role
CC       in the recruitment of phosphatidylcholine (PC),
CC       phosphatidylethanolamine (PE) and sphingomyelin (SM) molecules to
CC       nonraft membranes and to fu rther enrichment of SM and cholesterol
CC       in raft membranes in hepatocytes (PubMed:23468132). Required for
CC       proper phospholipid bile formation (By similarity). Indirectly
CC       involved in cholesterol efflux activity from hepatocytes into the
CC       canalicular lumen in the presence of bile salts in an ATP-
CC       dependent manner (PubMed:24045840). May promote biliary
CC       phospholipid secretion as canaliculi-containing vesicles from the
CC       canalicular plasma membrane (PubMed:9366571). In cooperation with
CC       ATP8B1, functions to protect hepatocytes from the deleterious
CC       detergent activity of bile salts (PubMed:21820390). Does not
CC       confer multidrug resistance (By similarity).
CC       {ECO:0000250|UniProtKB:P21440, ECO:0000269|PubMed:17523162,
CC       ECO:0000269|PubMed:21820390, ECO:0000269|PubMed:23468132,
CC       ECO:0000269|PubMed:24045840, ECO:0000269|PubMed:24594635,
CC       ECO:0000269|PubMed:24723470, ECO:0000269|PubMed:24806754,
CC       ECO:0000269|PubMed:7957936, ECO:0000269|PubMed:8898203,
CC       ECO:0000269|PubMed:9366571}.
CC   -!- CATALYTIC ACTIVITY: ATP + H(2)O + xenobiotic(In) = ADP + phosphate
CC       + xenobiotic(Out).
CC   -!- ENZYME REGULATION: Translocation activity is inhibited by the
CC       ATPase inhibitor vanadate and the calcium channel blocker
CC       verapamil (PubMed:17523162, PubMed:23468132). Translocation
CC       activity is enhanced by the addition of the bile salt taurocholate
CC       (PubMed:17523162, PubMed:23468132). {ECO:0000269|PubMed:17523162,
CC       ECO:0000269|PubMed:23468132}.
CC   -!- SUBUNIT: May interact with RACK1 (PubMed:19674157). Interacts with
CC       HAX1 (By similarity). {ECO:0000250|UniProtKB:Q08201,
CC       ECO:0000269|PubMed:19674157}.
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:23468132,
CC       ECO:0000269|PubMed:24045840, ECO:0000269|PubMed:24806754}; Multi-
CC       pass membrane protein {ECO:0000255|PROSITE-ProRule:PRU00441}.
CC       Apical cell membrane {ECO:0000269|PubMed:15258199,
CC       ECO:0000269|PubMed:19674157, ECO:0000269|PubMed:21820390,
CC       ECO:0000269|PubMed:24122873, ECO:0000269|PubMed:24594635,
CC       ECO:0000269|PubMed:24723470, ECO:0000269|PubMed:8898203}; Multi-
CC       pass membrane protein {ECO:0000255|PROSITE-ProRule:PRU00441}.
CC       Membrane raft {ECO:0000269|PubMed:23468132}. Cytoplasm
CC       {ECO:0000269|PubMed:24045840}. Cytoplasmic vesicle, clathrin-
CC       coated vesicle {ECO:0000250|UniProtKB:Q08201}. Note=Localized at
CC       the apical canalicular membrane of the epithelial cells lining the
CC       lumen of the bile canaliculi and biliary ductules (By similarity).
CC       Transported from the Golgi to the apical bile canalicular membrane
CC       in a RACK1-dependent manner (PubMed:19674157). Redistributed into
CC       pseudocanaliculi formed between cells in a bezafibrate- or PPARA-
CC       dependent manner (PubMed:15258199). Localized preferentially in
CC       lipid nonraft domains of canalicular plasma membranes
CC       (PubMed:23468132). {ECO:0000250|UniProtKB:P21440,
CC       ECO:0000269|PubMed:15258199, ECO:0000269|PubMed:19674157,
CC       ECO:0000269|PubMed:23468132}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=P21439-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P21439-2; Sequence=VSP_023263;
CC       Name=3;
CC         IsoId=P21439-3; Sequence=VSP_046258, VSP_023263;
CC         Note=No experimental confirmation available. Gene prediction
CC         based on EST data.;
CC   -!- INDUCTION: Up-regulated by PPARA (PubMed:24122873). Up-regulated
CC       by compounds that cause peroxisome proliferation, such as
CC       fenofibrate (at protein level). Up-regulated by bezafibrate
CC       (PubMed:15258199). Up-regulated by compounds that cause peroxisome
CC       proliferation, such as fenofibrate, bezafibrate and gemfibrozil
CC       (PubMed:24122873). {ECO:0000269|PubMed:15258199,
CC       ECO:0000269|PubMed:24122873}.
CC   -!- PTM: Phosphorylated (PubMed:24723470). Phosphorylation on Thr-34
CC       is required for PC efflux activity. Phosphorylation occurs on
CC       serine and threonine residues in a protein kinase A- or C-
CC       dependent manner (PubMed:24723470). May be phosphorylated on Thr-
CC       44 and Ser-49 (PubMed:24723470). {ECO:0000269|PubMed:24723470}.
CC   -!- PTM: Glycosylated (PubMed:17523162, PubMed:24723470,
CC       PubMed:21820390). {ECO:0000269|PubMed:17523162,
CC       ECO:0000269|PubMed:21820390, ECO:0000269|PubMed:24723470}.
CC   -!- DISEASE: Cholestasis, progressive familial intrahepatic, 3 (PFIC3)
CC       [MIM:602347]: A disorder characterized by early onset of
CC       cholestasis that progresses to hepatic fibrosis, cirrhosis, and
CC       end-stage liver disease before adulthood.
CC       {ECO:0000269|PubMed:11313315, ECO:0000269|PubMed:12671900,
CC       ECO:0000269|PubMed:17726488, ECO:0000269|PubMed:21119540,
CC       ECO:0000269|PubMed:24045840, ECO:0000269|PubMed:24594635,
CC       ECO:0000269|PubMed:24806754, ECO:0000269|PubMed:9419367}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- DISEASE: Cholestasis of pregnancy, intrahepatic 3 (ICP3)
CC       [MIM:614972]: A liver disorder of pregnancy. It presents during
CC       the second or, more commonly, the third trimester of pregnancy
CC       with intense pruritus which becomes more severe with advancing
CC       gestation and cholestasis. It causes fetal distress, spontaneous
CC       premature delivery and intrauterine death. Patients have
CC       spontaneous and progressive disappearance of cholestasis after
CC       delivery. Cholestasis results from abnormal biliary transport from
CC       the liver into the small intestine. {ECO:0000269|PubMed:10767346,
CC       ECO:0000269|PubMed:12746424, ECO:0000269|PubMed:15077010}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- DISEASE: Gallbladder disease 1 (GBD1) [MIM:600803]: One of the
CC       major digestive diseases. Gallstones composed of cholesterol
CC       (cholelithiasis) are the common manifestations in western
CC       countries. Most people with gallstones, however, remain
CC       asymptomatic through their lifetimes.
CC       {ECO:0000269|PubMed:11313316, ECO:0000269|PubMed:12891548,
CC       ECO:0000269|PubMed:22331132, ECO:0000269|PubMed:23533021,
CC       ECO:0000269|PubMed:24723470, ECO:0000269|Ref.2}. Note=The disease
CC       is caused by mutations affecting the gene represented in this
CC       entry.
CC   -!- SIMILARITY: Belongs to the ABC transporter superfamily. ABCB
CC       family. Multidrug resistance exporter (TC 3.A.1.201) subfamily.
CC       {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=CAA84542.1; Type=Miscellaneous discrepancy; Note=Probable cloning artifact.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/abcb4/";
CC   -!- WEB RESOURCE: Name=ABCMdb; Note=Database for mutations in ABC
CC       proteins;
CC       URL="http://abcmutations.hegelab.org/proteinDetails?uniprot_id=P21439";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M23234; AAA36207.1; -; mRNA.
DR   EMBL; EF034088; ABJ53424.1; -; Genomic_DNA.
DR   EMBL; AC005045; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC005068; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC006154; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH236949; EAL24174.1; -; Genomic_DNA.
DR   EMBL; CH236949; EAL24175.1; -; Genomic_DNA.
DR   EMBL; CH236949; EAL24176.1; -; Genomic_DNA.
DR   EMBL; CH471091; EAW76946.1; -; Genomic_DNA.
DR   EMBL; CH471091; EAW76947.1; -; Genomic_DNA.
DR   EMBL; CH471091; EAW76948.1; -; Genomic_DNA.
DR   EMBL; CH471091; EAW76950.1; -; Genomic_DNA.
DR   EMBL; CH471091; EAW76951.1; -; Genomic_DNA.
DR   EMBL; CH471091; EAW76952.1; -; Genomic_DNA.
DR   EMBL; Z35284; CAA84542.1; ALT_SEQ; mRNA.
DR   EMBL; X06181; CAA29547.1; -; mRNA.
DR   CCDS; CCDS5605.1; -. [P21439-2]
DR   CCDS; CCDS5606.1; -. [P21439-1]
DR   CCDS; CCDS5607.1; -. [P21439-3]
DR   PIR; JS0051; DVHU3.
DR   RefSeq; NP_000434.1; NM_000443.3. [P21439-2]
DR   RefSeq; NP_061337.1; NM_018849.2. [P21439-1]
DR   RefSeq; NP_061338.1; NM_018850.2. [P21439-3]
DR   RefSeq; XP_011514615.1; XM_011516313.2. [P21439-3]
DR   UniGene; Hs.654403; -.
DR   ProteinModelPortal; P21439; -.
DR   SMR; P21439; -.
DR   BioGrid; 111263; 2.
DR   IntAct; P21439; 3.
DR   STRING; 9606.ENSP00000265723; -.
DR   ChEMBL; CHEMBL1743129; -.
DR   DrugBank; DB01394; Colchicine.
DR   DrugBank; DB06414; Etravirine.
DR   DrugBank; DB06207; Silodosin.
DR   SwissLipids; SLP:000000384; -.
DR   TCDB; 3.A.1.201.3; the atp-binding cassette (abc) superfamily.
DR   iPTMnet; P21439; -.
DR   PhosphoSitePlus; P21439; -.
DR   BioMuta; ABCB4; -.
DR   DMDM; 126302568; -.
DR   MaxQB; P21439; -.
DR   PaxDb; P21439; -.
DR   PeptideAtlas; P21439; -.
DR   PRIDE; P21439; -.
DR   Ensembl; ENST00000265723; ENSP00000265723; ENSG00000005471. [P21439-1]
DR   Ensembl; ENST00000358400; ENSP00000351172; ENSG00000005471. [P21439-3]
DR   Ensembl; ENST00000359206; ENSP00000352135; ENSG00000005471. [P21439-2]
DR   Ensembl; ENST00000453593; ENSP00000392983; ENSG00000005471. [P21439-3]
DR   GeneID; 5244; -.
DR   KEGG; hsa:5244; -.
DR   UCSC; uc003uiv.2; human. [P21439-1]
DR   CTD; 5244; -.
DR   DisGeNET; 5244; -.
DR   GeneCards; ABCB4; -.
DR   HGNC; HGNC:45; ABCB4.
DR   HPA; HPA049395; -.
DR   HPA; HPA053288; -.
DR   MalaCards; ABCB4; -.
DR   MIM; 171060; gene.
DR   MIM; 600803; phenotype.
DR   MIM; 602347; phenotype.
DR   MIM; 614972; phenotype.
DR   neXtProt; NX_P21439; -.
DR   OpenTargets; ENSG00000005471; -.
DR   Orphanet; 69665; Intrahepatic cholestasis of pregnancy.
DR   Orphanet; 69663; Low phospholipid associated cholelithiasis.
DR   Orphanet; 79305; Progressive familial intrahepatic cholestasis type 3.
DR   PharmGKB; PA268; -.
DR   eggNOG; KOG0055; Eukaryota.
DR   eggNOG; COG1132; LUCA.
DR   GeneTree; ENSGT00530000062896; -.
DR   HOVERGEN; HBG080809; -.
DR   InParanoid; P21439; -.
DR   KO; K05659; -.
DR   OMA; SEDANYQ; -.
DR   OrthoDB; EOG091G0HVA; -.
DR   PhylomeDB; P21439; -.
DR   TreeFam; TF105193; -.
DR   Reactome; R-HSA-1989781; PPARA activates gene expression.
DR   Reactome; R-HSA-382556; ABC-family proteins mediated transport.
DR   GeneWiki; ABCB4; -.
DR   GenomeRNAi; 5244; -.
DR   PRO; PR:P21439; -.
DR   Proteomes; UP000005640; Chromosome 7.
DR   Bgee; ENSG00000005471; -.
DR   CleanEx; HS_ABCB4; -.
DR   ExpressionAtlas; P21439; baseline and differential.
DR   Genevisible; P21439; HS.
DR   GO; GO:0015629; C:actin cytoskeleton; IDA:HPA.
DR   GO; GO:0016324; C:apical plasma membrane; IDA:UniProtKB.
DR   GO; GO:0031526; C:brush border membrane; IEA:Ensembl.
DR   GO; GO:0030136; C:clathrin-coated vesicle; IEA:UniProtKB-SubCell.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0005925; C:focal adhesion; IDA:HPA.
DR   GO; GO:0005887; C:integral component of plasma membrane; TAS:ProtInc.
DR   GO; GO:0046581; C:intercellular canaliculus; IEA:Ensembl.
DR   GO; GO:0016020; C:membrane; TAS:ProtInc.
DR   GO; GO:0045121; C:membrane raft; IEA:UniProtKB-SubCell.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0042626; F:ATPase activity, coupled to transmembrane movement of substances; IDA:UniProtKB.
DR   GO; GO:0008525; F:phosphatidylcholine transporter activity; IDA:UniProtKB.
DR   GO; GO:0090554; F:phosphatidylcholine-translocating ATPase activity; IDA:UniProtKB.
DR   GO; GO:0005548; F:phospholipid transporter activity; TAS:Reactome.
DR   GO; GO:0008559; F:xenobiotic-transporting ATPase activity; IEA:UniProtKB-EC.
DR   GO; GO:0032782; P:bile acid secretion; ISS:UniProtKB.
DR   GO; GO:0007420; P:brain development; IEA:Ensembl.
DR   GO; GO:0033231; P:carbohydrate export; IEA:Ensembl.
DR   GO; GO:0071475; P:cellular hyperosmotic salinity response; IEA:Ensembl.
DR   GO; GO:0071312; P:cellular response to alkaloid; IEA:Ensembl.
DR   GO; GO:0071236; P:cellular response to antibiotic; IEA:Ensembl.
DR   GO; GO:1903413; P:cellular response to bile acid; IDA:UniProtKB.
DR   GO; GO:1905231; P:cellular response to borneol; IEA:Ensembl.
DR   GO; GO:0071549; P:cellular response to dexamethasone stimulus; IEA:Ensembl.
DR   GO; GO:0071392; P:cellular response to estradiol stimulus; IEA:Ensembl.
DR   GO; GO:0071217; P:cellular response to external biotic stimulus; IEA:Ensembl.
DR   GO; GO:1905232; P:cellular response to L-glutamate; IEA:Ensembl.
DR   GO; GO:0036146; P:cellular response to mycotoxin; IEA:Ensembl.
DR   GO; GO:0007623; P:circadian rhythm; IEA:Ensembl.
DR   GO; GO:0043215; P:daunorubicin transport; IEA:Ensembl.
DR   GO; GO:0046618; P:drug export; IEA:Ensembl.
DR   GO; GO:1990962; P:drug transport across blood-brain barrier; IEA:Ensembl.
DR   GO; GO:0060856; P:establishment of blood-brain barrier; IEA:Ensembl.
DR   GO; GO:1990963; P:establishment of blood-retinal barrier; IEA:Ensembl.
DR   GO; GO:0009914; P:hormone transport; IEA:Ensembl.
DR   GO; GO:0050892; P:intestinal absorption; IEA:Ensembl.
DR   GO; GO:0007595; P:lactation; IEA:Ensembl.
DR   GO; GO:0055088; P:lipid homeostasis; IDA:UniProtKB.
DR   GO; GO:0006629; P:lipid metabolic process; TAS:ProtInc.
DR   GO; GO:0035633; P:maintenance of permeability of blood-brain barrier; IEA:Ensembl.
DR   GO; GO:0060548; P:negative regulation of cell death; IEA:Ensembl.
DR   GO; GO:0045332; P:phospholipid translocation; IDA:BHF-UCL.
DR   GO; GO:0001890; P:placenta development; IEA:Ensembl.
DR   GO; GO:0032376; P:positive regulation of cholesterol transport; IDA:UniProtKB.
DR   GO; GO:0061092; P:positive regulation of phospholipid translocation; IDA:UniProtKB.
DR   GO; GO:2001140; P:positive regulation of phospholipid transport; IDA:UniProtKB.
DR   GO; GO:2001025; P:positive regulation of response to drug; IEA:Ensembl.
DR   GO; GO:0097327; P:response to antineoplastic agent; IEA:Ensembl.
DR   GO; GO:0046686; P:response to cadmium ion; IEA:Ensembl.
DR   GO; GO:1905233; P:response to codeine; IEA:Ensembl.
DR   GO; GO:1905237; P:response to cyclosporin A; IEA:Ensembl.
DR   GO; GO:0042493; P:response to drug; TAS:ProtInc.
DR   GO; GO:1901557; P:response to fenofibrate; ISS:UniProtKB.
DR   GO; GO:1903416; P:response to glycoside; IEA:Ensembl.
DR   GO; GO:0001666; P:response to hypoxia; IEA:Ensembl.
DR   GO; GO:0043278; P:response to morphine; IEA:Ensembl.
DR   GO; GO:1905235; P:response to quercetin; IEA:Ensembl.
DR   GO; GO:0097068; P:response to thyroxine; IEA:Ensembl.
DR   GO; GO:0033189; P:response to vitamin A; IEA:Ensembl.
DR   GO; GO:0033280; P:response to vitamin D; IEA:Ensembl.
DR   GO; GO:0055085; P:transmembrane transport; TAS:Reactome.
DR   GO; GO:0006810; P:transport; TAS:ProtInc.
DR   InterPro; IPR003593; AAA+_ATPase.
DR   InterPro; IPR011527; ABC1_TM_dom.
DR   InterPro; IPR003439; ABC_transporter-like.
DR   InterPro; IPR017871; ABC_transporter_CS.
DR   InterPro; IPR027417; P-loop_NTPase.
DR   Pfam; PF00664; ABC_membrane; 2.
DR   Pfam; PF00005; ABC_tran; 2.
DR   SMART; SM00382; AAA; 2.
DR   SUPFAM; SSF52540; SSF52540; 2.
DR   SUPFAM; SSF90123; SSF90123; 2.
DR   PROSITE; PS50929; ABC_TM1F; 2.
DR   PROSITE; PS00211; ABC_TRANSPORTER_1; 2.
DR   PROSITE; PS50893; ABC_TRANSPORTER_2; 2.
PE   1: Evidence at protein level;
KW   Alternative splicing; ATP-binding; Cell membrane; Complete proteome;
KW   Cytoplasm; Cytoplasmic vesicle; Disease mutation; Glycoprotein;
KW   Hydrolase; Intrahepatic cholestasis; Lipid transport; Membrane;
KW   Nucleotide-binding; Phosphoprotein; Polymorphism; Reference proteome;
KW   Repeat; Transmembrane; Transmembrane helix; Transport.
FT   CHAIN         1   1286       Phosphatidylcholine translocator ABCB4.
FT                                /FTId=PRO_0000093333.
FT   TOPO_DOM      1     50       Cytoplasmic. {ECO:0000250}.
FT   TRANSMEM     51     73       Helical. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00441}.
FT   TOPO_DOM     74    118       Extracellular. {ECO:0000250}.
FT   TRANSMEM    119    139       Helical. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00441}.
FT   TOPO_DOM    140    188       Cytoplasmic. {ECO:0000250}.
FT   TRANSMEM    189    210       Helical. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00441}.
FT   TOPO_DOM    211    217       Extracellular. {ECO:0000250}.
FT   TRANSMEM    218    238       Helical. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00441}.
FT   TOPO_DOM    239    296       Cytoplasmic. {ECO:0000250}.
FT   TRANSMEM    297    318       Helical. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00441}.
FT   TOPO_DOM    319    332       Extracellular. {ECO:0000250}.
FT   TRANSMEM    333    354       Helical. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00441}.
FT   TOPO_DOM    355    711       Cytoplasmic. {ECO:0000250}.
FT   TRANSMEM    712    732       Helical. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00441}.
FT   TOPO_DOM    733    755       Extracellular. {ECO:0000250}.
FT   TRANSMEM    756    776       Helical. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00441}.
FT   TOPO_DOM    777    831       Cytoplasmic. {ECO:0000250}.
FT   TRANSMEM    832    852       Helical. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00441}.
FT   TOPO_DOM    853    853       Extracellular. {ECO:0000250}.
FT   TRANSMEM    854    873       Helical. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00441}.
FT   TOPO_DOM    874    933       Cytoplasmic. {ECO:0000250}.
FT   TRANSMEM    934    956       Helical. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00441}.
FT   TOPO_DOM    957    972       Extracellular. {ECO:0000250}.
FT   TRANSMEM    973    994       Helical. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00441}.
FT   TOPO_DOM    995   1286       Cytoplasmic. {ECO:0000250}.
FT   DOMAIN       57    359       ABC transmembrane type-1 1.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00441}.
FT   DOMAIN      394    630       ABC transporter 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00434}.
FT   DOMAIN      711    999       ABC transmembrane type-1 2.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00441}.
FT   DOMAIN     1034   1279       ABC transporter 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00434}.
FT   NP_BIND     429    436       ATP 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00434}.
FT   NP_BIND    1069   1076       ATP 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00434}.
FT   REGION      625    647       Interaction with HAX1. {ECO:0000250}.
FT   MOD_RES      27     27       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P21440}.
FT   MOD_RES      34     34       Phosphothreonine.
FT                                {ECO:0000269|PubMed:24723470}.
FT   MOD_RES     660    660       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P06795}.
FT   CARBOHYD     91     91       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD     97     97       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   VAR_SEQ     929    975       Missing (in isoform 3). {ECO:0000305}.
FT                                /FTId=VSP_046258.
FT   VAR_SEQ    1094   1100       Missing (in isoform 2 and isoform 3).
FT                                {ECO:0000303|PubMed:2906314}.
FT                                /FTId=VSP_023263.
FT   VARIANT      34     34       T -> M (in GBD1; reduces efflux activity
FT                                for PC in a phosphorylation-dependent
FT                                manner; dbSNP:rs142794414).
FT                                {ECO:0000269|PubMed:22331132,
FT                                ECO:0000269|PubMed:24723470}.
FT                                /FTId=VAR_073728.
FT   VARIANT      47     47       R -> G (in GBD1; partly retained
FT                                intracellularly; reduces efflux activity
FT                                for PC in a phosphorylation-dependent
FT                                manner). {ECO:0000269|PubMed:22331132,
FT                                ECO:0000269|PubMed:23533021,
FT                                ECO:0000269|PubMed:24723470}.
FT                                /FTId=VAR_073729.
FT   VARIANT      47     47       R -> Q (found in patients with
FT                                cholangitis; unknown pathological
FT                                significance; dbSNP:rs372685632).
FT                                {ECO:0000269|PubMed:22331132}.
FT                                /FTId=VAR_073730.
FT   VARIANT      68     68       G -> R (in PFIC3; retained in the
FT                                reticulum endoplasmic; greatly reduced
FT                                expression).
FT                                {ECO:0000269|PubMed:24594635}.
FT                                /FTId=VAR_073731.
FT   VARIANT      70     70       G -> R (in PFIC3).
FT                                {ECO:0000269|PubMed:21119540}.
FT                                /FTId=VAR_073732.
FT   VARIANT      71     71       L -> H (in GBD1; dbSNP:rs780641693).
FT                                {ECO:0000269|PubMed:23533021}.
FT                                /FTId=VAR_073733.
FT   VARIANT      73     73       L -> V (in PFIC3 and GBD1;
FT                                dbSNP:rs8187788).
FT                                {ECO:0000269|PubMed:21119540,
FT                                ECO:0000269|PubMed:23533021}.
FT                                /FTId=VAR_073734.
FT   VARIANT      78     78       F -> C (in GBD1).
FT                                {ECO:0000269|PubMed:23533021}.
FT                                /FTId=VAR_073735.
FT   VARIANT      87     87       D -> E. {ECO:0000269|PubMed:16763017}.
FT                                /FTId=VAR_043078.
FT   VARIANT      95     95       P -> S (in dbSNP:rs377268767).
FT                                {ECO:0000269|PubMed:16763017}.
FT                                /FTId=VAR_043079.
FT   VARIANT      99     99       S -> F (in GBD1).
FT                                {ECO:0000269|PubMed:23533021}.
FT                                /FTId=VAR_073736.
FT   VARIANT     124    124       G -> S (in GBD1).
FT                                {ECO:0000269|PubMed:23533021}.
FT                                /FTId=VAR_073737.
FT   VARIANT     126    126       G -> E (in PFIC3).
FT                                {ECO:0000269|PubMed:17726488}.
FT                                /FTId=VAR_073738.
FT   VARIANT     138    138       W -> R (in PFIC3; dbSNP:rs72552781).
FT                                {ECO:0000269|PubMed:11313315}.
FT                                /FTId=VAR_043080.
FT   VARIANT     150    150       R -> K (in ICP3; dbSNP:rs757693457).
FT                                {ECO:0000269|PubMed:12746424}.
FT                                /FTId=VAR_043081.
FT   VARIANT     154    154       F -> S (in GBD1).
FT                                {ECO:0000269|PubMed:23533021}.
FT                                /FTId=VAR_073739.
FT   VARIANT     165    165       F -> I (in GBD1).
FT                                {ECO:0000269|PubMed:12891548,
FT                                ECO:0000269|PubMed:23533021}.
FT                                /FTId=VAR_043082.
FT   VARIANT     175    175       T -> A (found in patients with
FT                                gallbladder and cholestasis; unknown
FT                                pathological significance;
FT                                dbSNP:rs58238559).
FT                                {ECO:0000269|PubMed:11313316,
FT                                ECO:0000269|PubMed:12891548,
FT                                ECO:0000269|PubMed:15077010,
FT                                ECO:0000269|PubMed:16763017,
FT                                ECO:0000269|PubMed:17264802,
FT                                ECO:0000269|PubMed:17726488,
FT                                ECO:0000269|PubMed:22331132,
FT                                ECO:0000269|PubMed:23533021}.
FT                                /FTId=VAR_023501.
FT   VARIANT     201    201       T -> M (in PFIC3; greatly reduced
FT                                expression; alters efflux activity for
FT                                PC; dbSNP:rs753318087).
FT                                {ECO:0000269|PubMed:24594635}.
FT                                /FTId=VAR_073740.
FT   VARIANT     238    238       L -> V (in dbSNP:rs45596335).
FT                                {ECO:0000269|Ref.2}.
FT                                /FTId=VAR_020223.
FT   VARIANT     250    250       A -> P (in PFIC3).
FT                                {ECO:0000269|PubMed:17726488}.
FT                                /FTId=VAR_073741.
FT   VARIANT     263    263       I -> V (in dbSNP:rs45547936).
FT                                {ECO:0000269|Ref.2}.
FT                                /FTId=VAR_030763.
FT   VARIANT     286    286       A -> V (in PFIC3 and GBD1; does not alter
FT                                plasma membrane location; inhibits efflux
FT                                activity for PC; dbSNP:rs765478923).
FT                                {ECO:0000269|PubMed:17726488,
FT                                ECO:0000269|PubMed:22331132,
FT                                ECO:0000269|PubMed:23533021,
FT                                ECO:0000269|PubMed:24806754}.
FT                                /FTId=VAR_073742.
FT   VARIANT     301    301       M -> T (in GBD1; dbSNP:rs72552779).
FT                                {ECO:0000269|PubMed:12891548,
FT                                ECO:0000269|PubMed:23533021}.
FT                                /FTId=VAR_043083.
FT   VARIANT     320    320       S -> F (in ICP3, GBD1 and PFIC3; unknown
FT                                pathological significance; does not alter
FT                                plasma membrane location; does not
FT                                inhibit efflux activity for PC;
FT                                dbSNP:rs72552778).
FT                                {ECO:0000269|PubMed:11313316,
FT                                ECO:0000269|PubMed:12891548,
FT                                ECO:0000269|PubMed:15077010,
FT                                ECO:0000269|PubMed:17726488,
FT                                ECO:0000269|PubMed:21119540,
FT                                ECO:0000269|PubMed:22331132,
FT                                ECO:0000269|PubMed:23533021,
FT                                ECO:0000269|PubMed:24806754}.
FT                                /FTId=VAR_023502.
FT   VARIANT     346    346       S -> I (in PFIC3; dbSNP:rs67876345).
FT                                {ECO:0000269|PubMed:11313315}.
FT                                /FTId=VAR_043084.
FT   VARIANT     357    357       F -> L (in PFIC3).
FT                                {ECO:0000269|PubMed:17726488}.
FT                                /FTId=VAR_073743.
FT   VARIANT     364    364       A -> V (in PFIC3).
FT                                {ECO:0000269|PubMed:17726488}.
FT                                /FTId=VAR_073744.
FT   VARIANT     367    367       I -> V. {ECO:0000269|PubMed:16763017}.
FT                                /FTId=VAR_043085.
FT   VARIANT     395    395       E -> G (in PFIC3; dbSNP:rs72552777).
FT                                {ECO:0000269|PubMed:11313315}.
FT                                /FTId=VAR_043086.
FT   VARIANT     403    403       Y -> H (in PFIC3; does not alter
FT                                cytoplasmic and cell membrane location;
FT                                inhibits efflux activity for PC and
FT                                cholesterol; dbSNP:rs121918443).
FT                                {ECO:0000269|PubMed:17726488,
FT                                ECO:0000269|PubMed:21119540,
FT                                ECO:0000269|PubMed:24045840}.
FT                                /FTId=VAR_073745.
FT   VARIANT     406    406       R -> G (in GBD1).
FT                                {ECO:0000269|PubMed:23533021}.
FT                                /FTId=VAR_073746.
FT   VARIANT     406    406       R -> Q (found in patients with
FT                                cholangitis; unknown pathological
FT                                significance; dbSNP:rs763807769).
FT                                {ECO:0000269|PubMed:22331132}.
FT                                /FTId=VAR_073747.
FT   VARIANT     424    424       T -> A (in PFIC3).
FT                                {ECO:0000269|PubMed:11313315}.
FT                                /FTId=VAR_043087.
FT   VARIANT     425    425       V -> M (in PFIC3).
FT                                {ECO:0000269|PubMed:11313315}.
FT                                /FTId=VAR_043088.
FT   VARIANT     450    450       E -> G. {ECO:0000269|PubMed:16763017}.
FT                                /FTId=VAR_043089.
FT   VARIANT     459    459       D -> H (in PFIC3; retained in the
FT                                reticulum endoplasmic; greatly reduced
FT                                expression).
FT                                {ECO:0000269|PubMed:24594635}.
FT                                /FTId=VAR_073748.
FT   VARIANT     475    475       V -> A (in PFIC3).
FT                                {ECO:0000269|PubMed:17726488}.
FT                                /FTId=VAR_073749.
FT   VARIANT     479    479       P -> L (in PFIC3; greatly reduced
FT                                expression; alters efflux activity for
FT                                PC). {ECO:0000269|PubMed:24594635}.
FT                                /FTId=VAR_073750.
FT   VARIANT     481    481       L -> R (in PFIC3; does not alter
FT                                cytoplasmic and cell membrane location;
FT                                inhibits efflux activity for PC and
FT                                cholesterol).
FT                                {ECO:0000269|PubMed:24045840}.
FT                                /FTId=VAR_073751.
FT   VARIANT     510    510       N -> S (in GBD1; dbSNP:rs375315619).
FT                                {ECO:0000269|PubMed:23533021}.
FT                                /FTId=VAR_073752.
FT   VARIANT     511    511       A -> T (in PFIC3 and GBD1).
FT                                {ECO:0000269|PubMed:17726488,
FT                                ECO:0000269|PubMed:23533021}.
FT                                /FTId=VAR_073753.
FT   VARIANT     513    513       E -> K (in GBD1).
FT                                {ECO:0000269|PubMed:23533021}.
FT                                /FTId=VAR_073754.
FT   VARIANT     528    528       E -> D (in GBD1; unknown pathological
FT                                significance; dbSNP:rs8187797).
FT                                {ECO:0000269|PubMed:12891548,
FT                                ECO:0000269|PubMed:15077010,
FT                                ECO:0000269|PubMed:22331132,
FT                                ECO:0000269|PubMed:23533021,
FT                                ECO:0000269|Ref.2}.
FT                                /FTId=VAR_043090.
FT   VARIANT     535    535       G -> D (in PFIC3).
FT                                {ECO:0000269|PubMed:12671900}.
FT                                /FTId=VAR_043091.
FT   VARIANT     541    541       I -> F (in PFIC3 and GBD1;
FT                                dbSNP:rs66904256).
FT                                {ECO:0000269|PubMed:11313315,
FT                                ECO:0000269|PubMed:23533021}.
FT                                /FTId=VAR_043092.
FT   VARIANT     545    545       R -> H (in GBD1).
FT                                {ECO:0000269|PubMed:23533021}.
FT                                /FTId=VAR_073755.
FT   VARIANT     546    546       A -> D (in ICP3; disruption of protein
FT                                trafficking with subsequent lack of
FT                                functional protein at the cell surface;
FT                                dbSNP:rs121918441).
FT                                {ECO:0000269|PubMed:10767346}.
FT                                /FTId=VAR_023503.
FT   VARIANT     549    549       R -> H (in GBD1; dbSNP:rs761238221).
FT                                {ECO:0000269|PubMed:23533021}.
FT                                /FTId=VAR_073756.
FT   VARIANT     556    556       L -> R (in PFIC3).
FT                                {ECO:0000269|PubMed:11313315}.
FT                                /FTId=VAR_043093.
FT   VARIANT     558    558       E -> K (in PFIC3).
FT                                {ECO:0000269|PubMed:17726488}.
FT                                /FTId=VAR_073757.
FT   VARIANT     564    564       D -> G (in PFIC3).
FT                                {ECO:0000269|PubMed:11313315}.
FT                                /FTId=VAR_043094.
FT   VARIANT     589    589       H -> T (in GBD1; requires 2 nucleotide
FT                                substitutions).
FT                                {ECO:0000269|PubMed:23533021}.
FT                                /FTId=VAR_073758.
FT   VARIANT     590    590       R -> Q (found in patients with
FT                                gallbladder and cholestasis; unknown
FT                                pathological significance;
FT                                dbSNP:rs45575636).
FT                                {ECO:0000269|PubMed:12891548,
FT                                ECO:0000269|PubMed:16763017,
FT                                ECO:0000269|PubMed:17264802,
FT                                ECO:0000269|PubMed:17726488,
FT                                ECO:0000269|PubMed:19261551,
FT                                ECO:0000269|PubMed:23533021,
FT                                ECO:0000269|Ref.2}.
FT                                /FTId=VAR_043095.
FT   VARIANT     591    591       L -> Q (in GBD1; dbSNP:rs72552776).
FT                                {ECO:0000269|PubMed:12891548,
FT                                ECO:0000269|PubMed:23533021}.
FT                                /FTId=VAR_043096.
FT   VARIANT     593    593       T -> A (in PFIC3).
FT                                {ECO:0000269|PubMed:17726488}.
FT                                /FTId=VAR_073759.
FT   VARIANT     593    593       T -> M (in GBD1; dbSNP:rs571555115).
FT                                {ECO:0000269|PubMed:23533021}.
FT                                /FTId=VAR_073760.
FT   VARIANT     630    630       M -> V (in PFIC3; dbSNP:rs372476723).
FT                                {ECO:0000269|PubMed:17726488}.
FT                                /FTId=VAR_073761.
FT   VARIANT     647    647       E -> K (in GBD1).
FT                                {ECO:0000269|PubMed:23533021}.
FT                                /FTId=VAR_073762.
FT   VARIANT     651    651       T -> N (in dbSNP:rs45476795).
FT                                {ECO:0000269|Ref.2}.
FT                                /FTId=VAR_030765.
FT   VARIANT     652    652       R -> G (found in patients with
FT                                gallbladder and cholestasis; unknown
FT                                pathological significance;
FT                                dbSNP:rs2230028).
FT                                {ECO:0000269|PubMed:11313315,
FT                                ECO:0000269|PubMed:12746424,
FT                                ECO:0000269|PubMed:12891548,
FT                                ECO:0000269|PubMed:15077010,
FT                                ECO:0000269|PubMed:16763017,
FT                                ECO:0000269|PubMed:17264802,
FT                                ECO:0000269|PubMed:19261551,
FT                                ECO:0000269|PubMed:21119540,
FT                                ECO:0000269|Ref.2}.
FT                                /FTId=VAR_020225.
FT   VARIANT     701    701       L -> P (in PFIC3).
FT                                {ECO:0000269|PubMed:17726488}.
FT                                /FTId=VAR_073763.
FT   VARIANT     711    711       F -> S (in PFIC3; dbSNP:rs72552773).
FT                                {ECO:0000269|PubMed:11313315}.
FT                                /FTId=VAR_043097.
FT   VARIANT     715    715       T -> I (in PFIC3; dbSNP:rs138773456).
FT                                {ECO:0000269|PubMed:17726488}.
FT                                /FTId=VAR_073764.
FT   VARIANT     723    723       G -> E (in PFIC3).
FT                                {ECO:0000269|PubMed:17726488}.
FT                                /FTId=VAR_073765.
FT   VARIANT     726    726       P -> L (in GBD1; dbSNP:rs141677867).
FT                                {ECO:0000269|PubMed:23533021}.
FT                                /FTId=VAR_073766.
FT   VARIANT     726    726       P -> T (in PFIC3).
FT                                {ECO:0000269|PubMed:17726488}.
FT                                /FTId=VAR_073767.
FT   VARIANT     729    729       S -> L (in GBD1).
FT                                {ECO:0000269|PubMed:23533021}.
FT                                /FTId=VAR_073768.
FT   VARIANT     737    737       A -> V (in PFIC3; dbSNP:rs147134978).
FT                                {ECO:0000269|PubMed:17726488}.
FT                                /FTId=VAR_073769.
FT   VARIANT     742    742       G -> S. {ECO:0000269|PubMed:12891548}.
FT                                /FTId=VAR_043098.
FT   VARIANT     762    762       G -> E (in ICP3).
FT                                {ECO:0000269|PubMed:15077010}.
FT                                /FTId=VAR_043099.
FT   VARIANT     764    764       I -> L (in a heterozygous patient with
FT                                risperidone-induced cholestasis).
FT                                {ECO:0000269|PubMed:17264802}.
FT                                /FTId=VAR_043100.
FT   VARIANT     775    775       T -> M (found in patients with
FT                                cholangitis; unknown pathological
FT                                significance; dbSNP:rs148052192).
FT                                {ECO:0000269|PubMed:15077010,
FT                                ECO:0000269|PubMed:17726488,
FT                                ECO:0000269|PubMed:22331132}.
FT                                /FTId=VAR_043101.
FT   VARIANT     788    788       R -> Q (found in patients with
FT                                gallbladder and cholestasis; unknown
FT                                pathological significance;
FT                                dbSNP:rs8187801).
FT                                {ECO:0000269|PubMed:12891548,
FT                                ECO:0000269|PubMed:23533021,
FT                                ECO:0000269|Ref.2}.
FT                                /FTId=VAR_024359.
FT   VARIANT     840    840       A -> D (in PFIC3).
FT                                {ECO:0000269|PubMed:17726488}.
FT                                /FTId=VAR_073770.
FT   VARIANT     934    934       A -> T (found in patients with
FT                                gallbladder and cholestasis; unknown
FT                                pathological significance;
FT                                dbSNP:rs61730509).
FT                                {ECO:0000269|PubMed:12891548,
FT                                ECO:0000269|PubMed:23533021}.
FT                                /FTId=VAR_043102.
FT   VARIANT     954    954       G -> S (in PFIC3; dbSNP:rs779829759).
FT                                {ECO:0000269|PubMed:17726488}.
FT                                /FTId=VAR_073771.
FT   VARIANT     964    964       V -> T (requires 2 nucleotide
FT                                substitutions; found in patients with
FT                                cholangitis; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:22331132}.
FT                                /FTId=VAR_073772.
FT   VARIANT     975    975       L -> V (in GBD1; dbSNP:rs759787957).
FT                                {ECO:0000269|PubMed:23533021}.
FT                                /FTId=VAR_073773.
FT   VARIANT     978    978       S -> P (in PFIC3; alters efflux activity
FT                                for PC). {ECO:0000269|PubMed:24594635}.
FT                                /FTId=VAR_073774.
FT   VARIANT     983    983       G -> S (in PFIC3; dbSNP:rs56187107).
FT                                {ECO:0000269|PubMed:11313315}.
FT                                /FTId=VAR_043103.
FT   VARIANT    1082   1082       L -> Q (in a heterozygous patient with
FT                                amoxicillin/clavulanic acid-induced
FT                                cholestasis).
FT                                {ECO:0000269|PubMed:17264802}.
FT                                /FTId=VAR_043104.
FT   VARIANT    1084   1084       R -> W (in GBD1).
FT                                {ECO:0000269|PubMed:23533021}.
FT                                /FTId=VAR_073775.
FT   VARIANT    1125   1125       E -> K (in PFIC3; alters efflux activity
FT                                for PC). {ECO:0000269|PubMed:24594635}.
FT                                /FTId=VAR_073776.
FT   VARIANT    1161   1161       Missing (in GBD1).
FT                                /FTId=VAR_043105.
FT   VARIANT    1168   1168       P -> S (in GBD1; dbSNP:rs121918442).
FT                                {ECO:0000269|PubMed:11313316,
FT                                ECO:0000269|PubMed:12891548}.
FT                                /FTId=VAR_023504.
FT   VARIANT    1193   1193       A -> T (in PFIC3).
FT                                {ECO:0000269|PubMed:17726488}.
FT                                /FTId=VAR_073777.
FT   MUTAGEN      34     34       T->D: Does not inhibit efflux activity
FT                                for PC. {ECO:0000269|PubMed:24723470}.
FT   MUTAGEN      44     44       T->A: Reduces efflux activity for PC.
FT                                Does not alter apical membrane location.
FT                                {ECO:0000269|PubMed:24723470}.
FT   MUTAGEN      49     49       S->A: Reduces efflux activity for PC.
FT                                Does not alter apical membrane location.
FT                                {ECO:0000269|PubMed:24723470}.
FT   MUTAGEN     435    435       K->M: Inhibits efflux activity for PC and
FT                                cholesterol, but does not alter
FT                                glycosylation and surface expression in
FT                                the presence of taurocholate.
FT                                {ECO:0000269|PubMed:17523162}.
FT   MUTAGEN     953    953       A->D: Accumulates predominantly in
FT                                intracellular compartments with only a
FT                                small fraction at the plasma membrane and
FT                                inhibits partially the efflux activity
FT                                for PC. {ECO:0000269|PubMed:24806754}.
FT   MUTAGEN    1075   1075       K->M: Inhibits efflux activity for PC and
FT                                cholesterol, but does not alter
FT                                glycosylation and surface expression in
FT                                the presence of taurocholate.
FT                                {ECO:0000269|PubMed:17523162}.
SQ   SEQUENCE   1286 AA;  141523 MW;  9A9066F2292F2CCF CRC64;
     MDLEAAKNGT AWRPTSAEGD FELGISSKQK RKKTKTVKMI GVLTLFRYSD WQDKLFMSLG
     TIMAIAHGSG LPLMMIVFGE MTDKFVDTAG NFSFPVNFSL SLLNPGKILE EEMTRYAYYY
     SGLGAGVLVA AYIQVSFWTL AAGRQIRKIR QKFFHAILRQ EIGWFDINDT TELNTRLTDD
     ISKISEGIGD KVGMFFQAVA TFFAGFIVGF IRGWKLTLVI MAISPILGLS AAVWAKILSA
     FSDKELAAYA KAGAVAEEAL GAIRTVIAFG GQNKELERYQ KHLENAKEIG IKKAISANIS
     MGIAFLLIYA SYALAFWYGS TLVISKEYTI GNAMTVFFSI LIGAFSVGQA APCIDAFANA
     RGAAYVIFDI IDNNPKIDSF SERGHKPDSI KGNLEFNDVH FSYPSRANVK ILKGLNLKVQ
     SGQTVALVGS SGCGKSTTVQ LIQRLYDPDE GTINIDGQDI RNFNVNYLRE IIGVVSQEPV
     LFSTTIAENI CYGRGNVTMD EIKKAVKEAN AYEFIMKLPQ KFDTLVGERG AQLSGGQKQR
     IAIARALVRN PKILLLDEAT SALDTESEAE VQAALDKARE GRTTIVIAHR LSTVRNADVI
     AGFEDGVIVE QGSHSELMKK EGVYFKLVNM QTSGSQIQSE EFELNDEKAA TRMAPNGWKS
     RLFRHSTQKN LKNSQMCQKS LDVETDGLEA NVPPVSFLKV LKLNKTEWPY FVVGTVCAIA
     NGGLQPAFSV IFSEIIAIFG PGDDAVKQQK CNIFSLIFLF LGIISFFTFF LQGFTFGKAG
     EILTRRLRSM AFKAMLRQDM SWFDDHKNST GALSTRLATD AAQVQGATGT RLALIAQNIA
     NLGTGIIISF IYGWQLTLLL LAVVPIIAVS GIVEMKLLAG NAKRDKKELE AAGKIATEAI
     ENIRTVVSLT QERKFESMYV EKLYGPYRNS VQKAHIYGIT FSISQAFMYF SYAGCFRFGA
     YLIVNGHMRF RDVILVFSAI VFGAVALGHA SSFAPDYAKA KLSAAHLFML FERQPLIDSY
     SEEGLKPDKF EGNITFNEVV FNYPTRANVP VLQGLSLEVK KGQTLALVGS SGCGKSTVVQ
     LLERFYDPLA GTVFVDFGFQ LLDGQEAKKL NVQWLRAQLG IVSQEPILFD CSIAENIAYG
     DNSRVVSQDE IVSAAKAANI HPFIETLPHK YETRVGDKGT QLSGGQKQRI AIARALIRQP
     QILLLDEATS ALDTESEKVV QEALDKAREG RTCIVIAHRL STIQNADLIV VFQNGRVKEH
     GTHQQLLAQK GIYFSMVSVQ AGTQNL
//
